Market Overview

UPDATE: Jefferies Downgrades Infinity Pharmaceuticals to Hold on Limited Upside

Related INFI
3 Partnerships Pushing The Pharmaceutical Sector Forward
Benzinga's Top Upgrades

Jefferies reduced its rating on Infinity Pharmaceuticals (NASDAQ: INFI) from Buy to Hold but raised its price target from $18 to $21.

Jefferies noted, "In the absence of positive events, INFI has gained significant traction on increased visibility of IPI-145 in Ph1/2a (its achievable potential yet-to-be defined; YTD +130% vs. +30% for NBI). While biotech valuation is often based on perceived potential for early-stage assets, at EV of ~$470M (vs. ~$490M for peers), with limited clinical data and numerous competitors in development, we view a Hold rating as appropriate for INFI.."

Infinity Pharmaceuticals closed at $20.20 on Tuesday.

Latest Ratings for INFI

Sep 2014JMP SecuritiesUpgradesMarket PerformMarket Outperform
Sep 2014JefferiesMaintainsBuy
Sep 2014WedbushUpgradesUnderperformNeutral

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings


Related Articles (INFI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters